Back to results
US 10,449,260 B2Granted
Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
OwnerTheodosia Maina-Nock, Berthold Artur Nock +1inventors
InventorsTheodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Claims6
A composition comprising a radiolabeled biodegradable peptide analog and a neutral endopeptidase (NEP) inhibitor, wherein the radiolabeled biodegradable peptide analog is (111In-DOTA)-MG11.
Dependencies are inferred from the claim text.